As with most marketable currencies, equity in a biotech can suffer from deviations from this underlying data-supported value, which can result in over-pricing of assets that lack the intrinsic quality or robustness.
Such classifications are mechanisms of power which perpetuate inequalities grounded in cultural-conceptions of a person or behavior, rather than which are intrinsic to the subjects of such labels.